Investigation Report on China’s Basiliximab Market, 2019-2023


SKU: 1908402 Category: Tag:


Thrombolytic therapy is using drugs to dissolve thrombi and achieve revascularization so that the brain tissue of the blocked vascular perfusion area can regain blood oxygen. As fibrin is an important composition of thrombus, current thrombolytic therapy mainly use drugs such as Streptokinase, Urokinase and Tissue Plasminogen Activator (t-PA) to dissolve fibrin.
Thrombolytic drugs include three generations. The first generation is non-specific plasminogen activators such as Streptokinase and Urokinase; the second generation is represented by t-PA such as Alteplase and Prourokinase; the third generation includes Reteplase, Tenecteplase, Nateplase, Recombinant Human Urokinase, etc.
Although Urokinase is a thrombolytic drug of the first generation, it is widely used in China. It is an enzyme protein isolated from healthy human urine or cultured from human kidney tissue.
Urokinase acts directly on the endogenous fibrinolytic system. It can catalyze the cracking of plasminogen to plasmin which dissolves thrombi by degrading fibrin clots as well as the fibrinogen, coagulation factors V and VIII in blood circulation. With a rapid onset and good effect on newly formed thrombi, Urokinase can also increase the vascular enzymatic activity of adenosine diphosphate (ADP), inhibit ADP-induced platelet aggregation and prevent thrombosis. After intravenous infusion, the activity of plasmin in the patient will be significantly increased; after a few hours of drug withdrawal, the activity of plasmin will be restored. As a traditional thrombolytic drug that has been marketed in China for many areas, Urokinase is widely used to treat acute myocardial infarction, cerebral thrombosis, pulmonary vein thrombosis, lower extremity vein thrombosis and other forms of vascular thrombosis.
Economic development, aging population and unhealthy diet push up the incidence of thrombotic diseases in China, which boosts the demand for Urokinase. According to CRI’s market survey, in 2017, the sales value of Urokinase in China reached CNY 50.56 million, representing a CAGR of 7.90% from 2013 to 2017. The Urokinase by Nanjing Nanda Pharmaceutical Co., Ltd. took up the largest market share in China. Its market share was about 50.60% by sales value and about 38.50% by sales volume.
It is expected that the market size of Urokinase in China will continue to grow in the next few years.

Topics covered:
– Market size of Urokinase in China
– Competitive landscape of China’s Urokinase market
– Prices of Urokinase in China
– Favorable and unfavorable factors influencing China’s Urokinase market
– Prospect of China’s Urokinase market

Additional information


Geography Covered

Date Published




Table of Contents

Table of Contents
1 Relevant Concepts of Basiliximab
1.1 Indications for Basiliximab
1.2 Development History of Basiliximab in China
1.3 Patents and Government Approval on Basiliximab in China
1.4 Organ Transplantation and Kidney Transplantation in China

2 Sales of Basiliximab in China, 2013-2017
2.1 Sales Value of Basiliximab
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.1 Sales Volume of Basiliximab
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Basiliximab by Dosage Form in China, 2013-2017
2.3.1 Sales Volume
2.3.2 Sales Value

3 Analysis on Major Basiliximab Manufacturers in China, 2013-2018
3.1 Analysis on Market Share of Major Basiliximab Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Novartis
3.2.1 Enterprise Profile
3.2.2 Sales of Basiliximab by Novartis in China

4 Prices of Basiliximab in China, 2017-2018
4.1 Novartis (Simulect)
4.1.1 Retail Prices of Simulect in Different Parts of China
4.1.2 Price Trend of Basiliximab

5 Prospect of China’s Basiliximab Market, 2019-2023
5.1 Factors Influencing Development of China’s Basiliximab Market
5.1.1 Driving Forces and Market Opportunities
5.1.2 Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

Selected Charts
Chart Patents on Basiliximab in China
Chart Government Approval on Basiliximab in China
Chart Sales of Basiliximab in China, 2013-2017
Chart Sales Value of Basiliximab in Parts of China, 2013-2017
Chart Sales Volume of Basiliximab in China, 2013-2017
Chart Sales Volume of Basiliximab in Parts of China, 2013-2017
Chart Sales Value of Basiliximab Injections in China, 2013-2017
Chart Sales Value of Basiliximab by Novartis in China, 2013-2017
Chart Prices of Basiliximab by Novartis (Simulect) in Parts of China, 2017-2018
Chart Forecast on Sales Value of Basiliximab in China, 2019-2023